8
Participants
Start Date
December 31, 1999
Primary Completion Date
January 31, 2002
Study Completion Date
July 31, 2005
rituximab
375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
Memorial Sloan-Kettering Cancer Center, New York
Cancer Center and Beckman Research Institute, City of Hope, Duarte
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Walter Reed Army Medical Center, Washington D.C.
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Cross Cancer Institute, Edmonton
Collaborators (1)
Genentech, Inc.
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER